Organizers & Speakers

Dr. Barzilai is a Geroscientists, he is a chaired Professor of Medicine and Genetics and Director of the biggest Center to study the Biology of Aging and the principal investigator of the Einstein Nathan Shock Center and the Glenn Center for excellence in Biology of Aging. He was the recipient of an NIH Merit Award aiming to extend the healthy life span in rodents through biological interventions. He also studies families of centenarians that have provided genetic/biological insights on the protection against aging. Several drugs are developed based, in part, on these paradigm-changing studies. He now leads the SuperAgers Initiative (https://www.afar.org/superagers) to recruit 10,000 centenarians and their families to validate and discover new longevity genes. He is also leading the TAME (Targeting/Taming Aging with Metformin) multi-center study to prove that multi-morbidities of aging can be delayed in humans and change the FDA indications to allow for next-generation interventions (https://www.afar.org/tame-trial). He is also leading an initiative to discover biomarkers of aging that are changing with gerotherapeutics.

He is the author of over 300 peer-reviewed papers and a recipient of numerous prestigious awards, including the 2010 Irving S. Wright Award for Distinction in Aging Research. He is the 2018 recipient of the IPSEN Longevity award. He is on the board of AFAR, its scientific director, and a founding member of the Academy for Lifespan and HealthSpan, The Longevity Biotech Association, and Longevity Medicine Society. He co-founded CohBar and Lifesciences. He has been featured in prominent papers, podcasts, TV programs, and documentaries (3 TEDx and TEDMED). He has been consulting or presented the promise for targeting aging at The Singapore Prime Minister’s Office, the Prime Minister’s office in Israel, several International Banks, The Vatican, Pepsico, Milken Institute, Davos Economical Forum, and featured in The Wall Street Journal, New York Times, The Economist and Wired Magazine. His book Age Later was published in the June of 2020

James L. Kirkland, M.D., Ph.D., is the Noaber Foundation Professor of Aging Research at Mayo Clinic. Dr. Kirkland’s research is on the contribution of fundamental aging processes, particularly cellular senescence, to age-related and chronic diseases and development of agents and strategies for targeting fundamental aging mechanisms to treat age- and chronic disease-related conditions. Additional research areas include molecular and physiological mechanisms of age-related adipose tissue and metabolic dysfunction, frailty, and loss of resilience to infections and acute diseases in old age. Dr. Kirkland’s laboratory published the first article about agents that selectively eliminate senescent cells – senolytic drugs. Dr. Kirkland demonstrated that senolytic agents enhance healthspan and delay, prevent, or alleviate multiple age-related disorders and diseases in mouse models. He published the first composite biomarker score of senescent cell burden that is sensitive to drug interventions in humans and the first clinical trials of senolytic drugs. He is preparing or conducting clinical studies of senolytics, including for COVID-19, frailty in elderly women, Alzheimer’s disease, diabetes/obesity, osteoporosis, childhood cancer survivors, restoring function of organs from old donors to enable transplantation, idiopathic pulmonary fibrosis, pre-eclampsia, and others. He has more than 270 publications and holds over 80 patents. Dr. Kirkland is Principal Investigator of the Translational Geroscience Network (R33 AG061456), which brings together 8 academic institutions to translate healthspan interventions, including senolytics and other drugs that target fundamental aging processes, from bench to bedside. He has been a scientific advisory board member for several companies and academic organizations. He is President of the American Federation for Aging Research, a past member of the National Advisory Council on Aging of the National Institutes of Health, past chair of the Biological Sciences Section of the Gerontological Society of America, and past member of the Clinical Trials Advisory Panel of the National Institute on Aging. He is a board-certified specialist in internal medicine, geriatrics, and endocrinology and metabolism. Dr. Kirkland is the 2020 recipient of the Irving S. Wright Award of Distinction from the American Federation for Aging Research.

Oon Chiew Seng Professor in Medicine, Healthy Ageing and Dementia Research, Director at Centre for Healthy Longevity, National University Health System, National University of Singapore

Professor of Gerontology, Vrije Universiteit Amsterdam, The Netherlands

Andrea Maier (1978), a Fellow of the Royal Australasian College of Physicians (FRACP), graduated in Medicine (MD) 2003 from the University of Lübeck (Germany), was registered 2009 in The Netherlands as Specialist in Internal Medicine-Geriatrics and was appointed Full Professor of Gerontology at Vrije Universiteit Amsterdam (The Netherlands) in 2013. She was the head of Geriatrics at the Vrije Universiteit Medical Center from 2012 to 2016. From 2016 to early 2021 Professor Maier served as Divisional Director of Medicine and Community Care at the Royal Melbourne Hospital, Australia, and as Professor of Medicine and Aged Care at the University of Melbourne, Australia. She continued her career at the National University of Singapore as Co-Director of the Centre for Healthy Longevity. Professor Maier’s research focuses on unraveling the mechanisms of ageing and age-related diseases. She is heading international longitudinal cohort studies and geroscience interventions. During the last 12 years she has published more than 370 peer-reviewed articles, achieving an H index of 68, spearheading the significant contributions of her highly acclaimed innovative, global, multidisciplinary @Age research group. She is a frequent guest on radio and television programs to disseminate aging research and an invited member of several international academic and health policy committees, including the WHO. She is the past President of The Australian and New Zealand Society for Sarcopenia and Frailty Research, the Founding President of the Healthy Longevity Medicine Society and serves as selected Member of The Royal Holland Society of Sciences and Humanities.

Dr. Eric Verdin is the President and CEO of the Buck Institute for Research on Aging – a pioneering biomedical research institute dedicated to ageing and age-related disease.

A native of Belgium, Dr. Verdin received his Doctorate of Medicine (MD) from the University of Liege and completed additional clinical and research training at Harvard Medical School. He has held faculty positions at the University of Brussels, the National Institutes of Health (NIH), and the Picower Institute for Medical Research. Dr. Verdin is also currently a professor of medicine at the University of California, San Francisco.

He joined the Gladstone Institute of Virology and Immunology in 1997, becoming the associate director in 2004. In 2016 Dr. Verdin established his laboratory at the Buck Institute for Research on Aging to study the relationship between ageing and the immune system.

He is in the top one percent of cited scientists and has been recognized for his research with a Glenn Award for Research in Biological Mechanisms of Aging and a senior scholarship from the Ellison Medical Foundation. He has published more than 220 scientific papers and holds more than 15 patents.

He is an elected member of several scientific organizations, including the American Association for the Advancement of Science, the American Society for Clinical Investigation, and the Association of American Physicians. He also serves on the advisory council of the National Institute on Drug Abuse at the National Institutes of Health.

Dr. Verdin has extensive experience working with biotech companies, including Novartis, Roche, Pfizer, and now Hooke London.

Thomas A. Rando, MD, PhD is Director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA, where he is also Professor of Neurology and of Molecular, Cell, and Developmental Biology. Dr. Rando received his AB, MD, and PhD degrees from Harvard University and then completed a residency in neurology at UCSF and postdoctoral training at Stanford University. Prior to coming to UCLA in 2021, he had been on the faculty Stanford University School of Medicine in the Department of Neurology and Neurological Sciences. At Stanford, Dr. Rando was the founding Director of the Glenn Center for the Biology of Aging, a member of the Institute for Stem Cell Biology and Regenerative Medicine, founding deputy director of the Stanford Center on Longevity, and Chief of Neurology at the Palo Alto VA Medical Center. Dr. Rando’s research focuses on stem cell biology and the biology of aging. His stem cell work has focused on the regulation of cell fate decisions with a particular interest in stem cell quiescence. He has been a pioneer in the field of systemic factors as regulators of cellular aging beginning with seminal studies done in his laboratory using the technique of heterochronic parabiosis. These studies have formed a foundation of current approaches to epigenetic rejuvenation. He is a scientific founder of Fountain Therapeutics whose mission is to develop therapies for diseases of aging based these fundamental biological principles.

Dr. Rando has published over 200 peer-reviewed articles and has trained over 100 students, fellows, and visiting scholars, most of whom have continued in biomedical research careers. Dr. Rando has received numerous awards including an NIH Director’s Pioneer Award, an Ellison Medical Foundation Senior Scholar Award in Aging, the “Breakthroughs in Gerontology” Award from the American Federation for Aging Research, and a Transformative Research Award from the NIH. He is a Fellow of the American Association for the Advancement of Science, a member of the National Academy of Medicine, and a member of the American Academy of Arts and Sciences.

Professor Strauss is a highly accomplished pediatrician and neonatology specialist, with a wealth of experience in her field. She received her medical degree from the Rappaport Institute of Technology in Haifa, and holds an MPH from the Harvard School of Public Health. In addition, she holds a Professor degree from Tel Aviv University.

For over a decade, Professor Strauss has served as the Director of the Neonatology Department at Sheba Medical Center. In this role, she has published numerous articles and reviews in her field, and has been a member of numerous committees in her area of expertise.

In the last two years, Professor Strauss has taken on the responsibility of developing one of the first academic and clinical research centers for longevity in a public hospital. The Longevity Academic Center, which Professor Strauss leads, aims to improve our understanding of aging and longevity, and to identify opportunities for improving the quality of life and function in older age. The center focuses on the study of health and wellness from young adulthood through the centenarian age group (45-100 years old), including cutting edge diagnostic techniques, the analysis and monitoring of health biomarkers, and the study of multidisciplinary interventions.

Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine (insilico.com), a leader in next-generation artificial intelligence technologies for drug discovery and biomarker development. Under his leadership, Insilico raised over $415 million in multiple rounds from expert investors, opened R&D centers in six countries or regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions, nominated 8 preclinical candidates, and entered human clinical trials with AI-discovered novel target and AI-designed novel molecule. Since 2015 he invented critical technologies in the field of generative adversarial networks (GANs) and reinforcement learning (RL) for generation of novel molecular structures with the desired properties and generation of synthetic biological and patient data. Since 2012 he published over 160 peer-reviewed research papers and 2 books.

He founded and co-chairs the Annual Aging Research, Drug Discovery and AI Forum (9th annual in 2022), the world’s largest event on aging in the pharmaceutical industry. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.

Internal medicine specialist

Internal medicine:
Chief physician associate of internal medicine and oncology at University Hospital Renji of Jiaotong University, Shanghai.
Emergency medicine physician at the Shanghai East International Medical Center

Longevity: Longevity physician at Human Longevity Inc.

Healthy Longevity Medicine Society, Vice-president
Longevity Science Foundation, Head of the Visionary Board

Dr. Christine Huang Yuan is the Technology Transfer Director of Hong Kong Quantum AI Lab and was selected as one of Forbes China 2020 “30 Under 30 (Healthcare and Science)”. Christine has vast experience in the biotechnology field, and shares her professional insights as a biomedicine investment consultant for China Internet Investment Finance Holding Limited (stock code: 0810.HK) and as a consultant to Insilico Medicine. She is also a member of the Advisory Board of Wing Wah Charity Foundation Hong Kong, and a Fellow of the Royal Society of Medicine.

Christine graduated from the Li Ka Shing Faculty of Medicine of the University of Hong Kong and trained in the neurology department of Queen Mary Hospital in Hong Kong, where she participated in several large-scale international clinical trials. She is also a Senior Research Associate at the University of Hong Kong. Dr. Huang is a translational medicine expert especially in the fields of AI-driven medicine, neurodegenerative disease and cancer treatment. She is also the founder and CEO of CSG Biotechnology Limited.

Dr. Rafael de Cabo is Chief of the Translational Gerontology Branch at the National Institute on Aging, National Institutes of Health, USA.

Dr. de Cabo earned his Ph.D. in 2000 from the Department of Foods and Nutrition at Purdue University. He received a postdoctoral position in the Laboratory of Neurosciences at the National Institute on Aging in Baltimore, Maryland. In 2004, he was appointed as a tenure track investigator in the Laboratory of Experimental Gerontology. He is now a senior investigator and Chief of the Translational Gerontology Branch at NIA. His research has focused on the effects of nutritional interventions on basic mechanisms of aging and age-related diseases, the effects of caloric restriction on aging, and pharmacological interventions for healthy aging. Ultimately his research aims to identify interventions that will improve healthspan and lifespan with translational potential to benefit human aging.

Joan Mannick is the Chief Executive Officer and Co-Founder of Tornado Therapeutics which is developing next generation mTOR inhibitors to extend healthy lifespan. Prior to joining Tornado, Joan Mannick was Head of Research and Development at Life Biosciences, a biotechnology company advancing treatments for age-related diseases by targeting aging biology. Prior to joining Life Biosciences, Dr. Mannick was Co-Founder and Chief Medical Officer of resTORbio which was a spinout of a clinical program targeting aging biology that she led as an Executive Director at the New Indications Discovery Unit of the Novartis Institutes of Biomedical Research. Prior to Novartis, Dr. Mannick was a Medical Director at Genzyme working in multiple therapeutic areas and was faculty member at Harvard Medical School and University of Massachusetts Medical School. Her NIH-sponsored laboratory focused on the role of protein S-nitrosylation in physiology and pathophysiology.

Dr. Mannick received her A.B. from Harvard College and her M.D. from Harvard Medical School. She completed her residency in Internal Medicine at Brigham and Women’s Hospital and an Infectious Disease fellowship as part of the Harvard Combined Infectious Disease Program

Dr. Shai Efrati is a professor at Sackler School of Medicine and the Sagol School of Neuroscience of Tel Aviv University and the director of the Sagol center for hyperbaric medicine and research at Shamir (Assaf-Harofeh) Medical Center in Israel. The center, under Prof. Efrati management, has become the largest hyperbaric center worldwide, currently treating more than 350 patients per day. Prof. Efrati is also the director of Research & Development at the Medical center, affiliated to Tel-Aviv University. Taking the two passions/positions together Dr. Efrati has initiated a research program focusing on the neuroplasticity (regeneration of damage brain tissue) looking at the brain as a tissue and characterizing the non-healing wounds in the brain and bottle necks that prevents their recover. In addition to diagnosis and characterizing, neuroplasticity can be induced using dedicated protocols of Hyperbaric Oxygen Therapy (HBOT). The newly used HBOT protocol induce brain and tissue repairment by fluctuations in oxygen and pressure that initiate regenerative biological cascade usually happens during hypoxia in hyperoxic condition- the so called Hyperoxic-Hypoxic paradox (HHP). The clinical studies proved that HHP can induce neuroplasticity in different types of brain injuries such as stroke, Traumatic Brain Injury, post-COVID and central pain syndromes even years after the acute Insult.

The insight gained on the regenerative capacity using the HHP has led to one of the most comprehensive research programs ever done on the so-called age related functional decline. The results from this ongoing program demonstrate, for the first time in normal aging population, that neurons and blood vessels in the brain can be regenerated, cognitive function improve, cardiac functions improve, sexual and physical function improve and that even the biology at the cellular level can be reverse (elongation of telomers and reduce senescent cells).

Prof. Eyal Zimlichman is an internal medicine physician, a health care executive and a researcher focused on assessing and improving health care quality and value, patient engagement and patient safety.

Prof. Zimlichman currently serves as chief transformation officer and chief innovation officer at Sheba Medical Center, Israel’s largest hospital. In this position, he oversees the transformation efforts carried out at the medical center as it aims to redesign healthcare to be patient centric, while being more effective, efficient and equitable. For these reasons, Prof. Zimlichman founded Sheba’s global innovation arm, ARC (Accelerate, Redesign and Collaborate). Prior to this, Prof. Zimlichman held the position of chief medical officer and before that as chief quality officer, both at Sheba.

Preceding his work at Sheba, Prof. Zimlichman held the position of lead researcher at Partners Health Care Clinical Affairs Department in Boston where he was involved in the efforts to bring about a strategic care redesign initiative. In that capacity, Prof. Zimlichman established their program for collecting and reporting patient reported outcomes across the continuum of care, a program that earned international appraisal. During that time, Prof. Zimlichman held an appointment at Brigham and Women’s Hospital and Harvard Medical School affiliated Center for Patient Safety Research and Practice, where he conducted research on implementing technology to improve quality and patient safety.

Prof. Zimlichman is a founding member of the International Academy of Quality and Safety in Health Care and an international expert at the International Society of Quality in Healthcare (ISQua). He also served as an advisor to the Office of the National Coordinator for Health Information Technology in the U.S. Department of Health and Human Services. In 2007, Prof. Zimlichman was selected as a member of Sheba’s Talpiot Medical Leadership Program, a program aimed at advancing the brightest young physicians into leadership roles. In 2017, he was appointed head of the program. Prof. Zimlichman earned his MSc in Healthcare Management from the Harvard School of Public Health and has earned his MD at the Technion Israel Institute of Technology.

Prof Amir Amedi is a multidisciplinary researcher with an educational background in biology, music, computational neuroscience, and clinical experience (Harvard, NIH). He is a pioneer in multisensory and brain plasticity research and won dozens of international awards. His discoveries were published in prestigious scientific and general-public journals (Nature, NYT, Wired) and he has published over 100 papers, patents, and book chapters. In 2019 he founded The Baruch Ivcher Institute For Brain, Cognition & Technology, a unique lab that inspires innovation. Recently he also founded two start-up companies, Remepy, a software drug combination company and DaVinci Neuroscience pioneering multisense brain technology. Prof Amedi is a Genius 100 Visionary fellow and recipient of the Krill prize of the Wolf foundation. He is known for making science accessible and his research has helped reshape some of neuroscience’s most fundamental questions and theories, for example, he helped revise the critical periods theory (1981 Nobel-Prize).

Brenda Ramokopelwa is a Futurist with ethical referents, Keynote Speaker, and Award-Winning Risk and data Governance professional . She a co- founder of Afrolongevity and CEO of the Transdisciplinary Agora for Future Discussion (TAFFD’s) a non profit organization focused on ethical use of science and technology to solve societal problems . She serves on 4IR policy advisory board at Media, Information, Technology and Education Authority in South Africa as well as the Ethics and Futurist Board of Lifeboat Foundation, USA. She is a regular contributor to local and international journals and magazines. Brenda has been featured on various local and international media and has done interviews with futurist media outlets like Transhumanist Enlightenment Salon USA, World Talent Economic Forum, and recently by a Global ranking Futurist, Ross Dowson, on “Thrive on Overload.”

Prof. Jaron Rabinovici is an Obstetrician and Gynecologist, a health care executive and a researcher focused on assessing and improving female health care.

He graduated from the School of Mediciane of the Vienna University, Austria, and trained during his residency at the Department of Obstetrics and Gynecology at the Sheba Medical Center in Israel. Following he performed a Fellowship in Reproductive Endocrinology under Prof. Bob Jaffe at the University of California, San Francisco (UCSF). After his Fellowship he returned to the Sheba Medical Center and continued his research at UCSF as a Visiting Professor for several years. Currently he is a Professor at the Tel Aviv University and he served until recently as Head of Department and Vice-Chairman of the Division of Obstetrics and Gynecology at the Sheba Medical Center, Israel’s largest hospital.

As part of his managerial activities Prof. Rabinovici works with “Sheba Global” and oversees and conducts clinical and scientific collaborations between Sheba and various foreign Women’s Health Departments (China, Kazakhstan, UAE, USA, etc.)

His main field of clinical and research activities involve Reproductive Endocrinology and he specializes and studies hormonal imbalances, infertility and (peri-)menopausal changes. Prof. Rabinovici has been active both in many clinical, research, managerial and biotech activities. He has published many significant scientific articles, has conducted international and national multi-center studies, has given invited lectures around the world and has participated and organized international and national scientific meetings. His research activities have earned him international awards and prizes (Fogarty, Fulbright, Bi-National and Yad Hanadiv, American Fertility Society grants among others). In addition, Jaron has experience in the biotechnology field, he is involved in Femtech/Biotech activities of different companies and shares his professional insights as a biomedicine consultant.

Over the last years Jaron’s interest have evolved shifted towards the connection between female health in during reproductive years, obstetrics and perimenopause, the correct female ovarian hormonal balance and healthy longevity. His clinical and research working hypothesis surrounds the notion that women in general live longer and stay healthier (than men) for many years because of the positive effects of balanced ovarian hormones. In contrast, women with irregular ovarian activities show increased morbidity and increased mortality rates. Therefore, there he regards the important role of gynecologists in general and specifically reproductive endocrinologists in correcting and treating hormonal imbalances, thus promoting “Healthy Longevity”.

Prof. Karen B. Avraham is the Dean of the Faculty of Medicine at Tel Aviv University and holds the Drs. Sarah and Felix Dumont Chair for Research of Hearing Disorders. She heads the Laboratory of Neural and Sensory Genomics in the Department of Human Molecular Genetics and Biochemistry and is affiliated with the Sagol School of Neuroscience and Safra Center for Bioinformatics. Born in Canada and raised in the U.S., she completed a B.A. in Biology at Washington University in St. Louis, a Ph.D. in Genetics at the Weizmann Institute in Israel, and post-doctoral training at the National Cancer Institute in Maryland. Prof. Avraham leads the effort in the discovery of disease genes and the use of models for therapy, with an emphasis on precision medicine. She has over 150 publications in international journals and has mentored over 130 undergraduate, MSc, PhD, MD-PhD students and post-docs. She was founding director of the Healthy Longevity Research Center and of the Aufzien Family Center for the Prevention and Treatment of Parkinson’s Disease at Tel Aviv University. Prof. Avraham founded and leads the Tel Aviv University M.Sc. program in Medical Sciences with a specialty in Genetic Counseling, the Single Cell Genomics Core, and the Biomed@TAU Research Hubs. Prof. Avraham was awarded, among others, the TEVA Prize for Groundbreaking Research in Rare Diseases and the Teva Founders Prize on Breakthroughs. She has been a visiting scholar at the Harvard Medical School and the University of Washington in Seattle. Prof. Avraham was recently appointed to the Faculty of Scholars of the Human Genome Organization, is an elected member of EMBO and of the Collegium Oto-Rhino-Laryngologicum Amicitiae Sacrum (CORLAS). She is a founding member of the International Society for Inner Ear Therapeutics (ISIET), a member of the Lancet Commission on Hearing Loss and of the CureGRIN Scientific Advisory Board. The research in her laboratory is currently funded by a National Institutes of Health R01, the Israel Science Foundation Breakthrough Research Grant, the Israel Precision Medicine Partnership Program (IPMP), the Israel-US Binational Science Foundation, and the Ernest and Bonnie Beutler Research Program of Excellence in Genomic Medicine Award.

Collin Yvès Ewald is a molecular biologist and a assistant professor at ETH Zurich in the Institute for Translational Medicine (ITM), where he leads the Laboratory of Extracellular Matrix Regeneration (https://en.wikipedia.org/wiki/Collin_Y._Ewald). His research focuses on the remodeling of the extracellular matrix during aging and upon longevity interventions (https://www.karger.com/Article/Abstract/504295). www.ewaldlab.com. Dr Ewald is the founder and currently the president of the Swiss Society for Aging Research (www.ssfar.ch).

Garri is a seasoned business angel with an extensive track record in tech business and an early investor in science-intensive ventures, such as Insilico Medicine, Basepaws, Deep Longevity. Prior to founding LongeVC, he co-founded Longenesis — a medical technology startup company working towards providing a technological bridge between Healthcare institutions and the BioTech industry with an aim to help identify and unlock the hidden value of biomedical data to accelerate the novel drug and treatment discovery and provide better help to those in need. In 2021, Garri became Director of the Board at Longevity Science Foundation — a Swiss and USA based non-profit organisation advancing human longevity by funding research and development of medical technologies to extend the healthy human lifespan.

Driven and resilient, Garri is passionate about longevity, aging research, personalised medicine, psychedelic research, web3 and blockchain.

Ilia Stambler, PhD, is the Chief Science Officer and Chairman of Vetek (Seniority) Association – the Movement for Longevity and Quality of Life, Israel (http://www.longevityisrael.org/). He is a fellow at the Department of Science, Technology and Society, Bar Ilan University, Israel.

He received his PhD at the Department of Science, Technology and Society, Bar Ilan University. His thesis explored the “History of Life-extensionism in the Twentieth Century” which resulted in an encompassing compendium on the history of aging and longevity research (http://www.longevityhistory.com/). His research has focused on the historical and social implications of aging and longevity research, including ethical, policy and regulatory implications. He has also been involved in mathematical modeling of aging and aging-related diseases, utilizing information-theoretical measures, with high impact publications. He is the author of the books “A History of Life-extensionism in the Twentieth Century” and “Longevity Promotion: Multidisciplinary Perspectives” and over 60 academic papers (journal articles and book chapters). He has been an invited speaker in over 50 academic conferences, over half of which he co-organized and/or co-chaired.

He is actively involved in advocacy for aging and longevity research, serving as an executive committee member of the International Society on Aging and Disease (ISOAD http://www.isoad.org/) and International Longevity Alliance (ILA http://www.longevityalliance.org; www.longevityforall.org), trustee and director at the Biogerontology Research Foundation (BGRF https://www.biogerontology.info/), fellow and policy director at the Global Healthspan Policy Institute (GHPI https://healthspanpolicy.org/).

Iris Shai, RD, PhD, is a Professor of Nutrition and Epidemiology at BGU in the field of nutrition, aging and chronic diseases, Adjunct Professor at Harvard University & Honorary Professor in Leipzig University, Germany. Shai is the chair of the International center of Health Innovation& Nutrition, and a member in the Government Health Ministry Committee for healthy Nutrition Regulations in Israel. Her focuses are obesity, diabetes, aging, cognition, epigenetics, microubioum and cardiometabolic risk, while performing long-term, large scale, compressive dietary randomized controlled trials (RCTs) in standards of drugs trials, and long-term cohorts. Following her fellowship, awarded with Fulbright, in Harvard School of Public Health, where she focused on traditional and non-traditional biomarkers for CVD, she leaded, with her international research team, the 2-year Dietary Intervention Randomized Controlled Trial (DIRECT) and 4-year follow-up (A Dietary Intervention- Randomized Controlled Trial (DIRECT) Study), comparing the effects of dietary strategies on cardiometabolic risk and plaque regression. In her next trial , CASCADE (The CArdiovasCulAr Diabetes & Ethanol (CASCADE) Trial) she addressed the 2-year effect of moderate alcohol in type 2 diabetes and her recent whole-body MRI trial ,CENTRAL (Diet and Body Composition (CENTRAL)), focused on dynamic of human specific fat depots and fuel metabolism across dietary strategies. Recently, she completed the DIRECT PLUS trial (Effects of Green-MED Diet Via the Gut-fat-brain Axis (DIRECT-PLUS)), which explores the effect of green Med diet, high- polyphenols on the gut-fat-brain axis. In this trial new horizons were explored, related to Autologous Fecal Microbiota Transplantation, brain atrophy attenuation and epi-genetics. The above-mentioned clinical trials serve in global nutritional guidelines in the field of obesity, cardiology, diabetes and fatty liver diseases. Currently, Shai directs the FIT project (Follow Intervention Trials) project which aims to identify predictors & drivers determining personal health outcome, as age-related brain atrophy; as an integration of four long-term, large scale dietary clinical trials. The FIT will leverage huge omics data bank from various human specimen, MRI scans and health outcomes toward personal medicine approach.
Shai teaches and counselling in the areas of Novel Technologist in Dietary Clinical Trials and Effective Scientific Writing.

Nikolina Lauc, Co-Founder & CEO at GlycanAge, is a successful entrepreneur with 12 years of experience and is now on a mission to unlock the human glycome for preventive health and longevity. She has built and scaled start-ups in the field of SaaS, travel, and consumer health to multi-million revenue businesses with a valuation of over US$ 25M. She’s co-inventor of 1 patent in the Women’s health diagnostics space. Fellow at Foresight Institute and co-founder of Women for Longevity.

Dr. Gil Blander is internationally recognized for his research in the basic biology of aging and translating research discoveries into new ways of detecting and preventing age-related conditions. He leads a team of biology, nutrition & exercise physiology experts, and data scientists at InsideTracker, and has been featured in CNN Money, The New York Times, Forbes, Financial Times, The Boston Globe to name a few.

Dr. Gil Blander received a Ph.D. in biology from the Weizmann Institute of Science and completed his Post Doctoral fellowship at MIT, before going on to found InsideTracker. InsideTracker was founded in 2009 by top scientists from acclaimed universities in the fields of aging, genetics, and biology, InsideTracker is a truly personalized nutrition and performance system. Our mission is to help people add years to their lives and life to their years by optimizing their bodies from the inside out. By analyzing your body’s data, we can give you a crystal clear picture of what’s going on inside you along with a science-backed action plan for improving your health and becoming your best self.

Eran Segal is a Professor at the Department of Computer Science and Applied Mathematics at the Weizmann Institute of Science, heading a lab with a multi-disciplinary team of computational biologists and experimental scientists in the area of Computational and Systems biology. His group has extensive experience in machine learning, computational biology, and analysis of heterogeneous high-throughput genomic data. His research focuses on Microbiome, Nutrition, Genetics, and their effect on health and disease. His aim is to develop personalized medicine based on data from large-scale and deeply phenotyped human cohorts.

Prof. Segal published over 200 publications, and received several awards and honors for his work, including the Overton prize, awarded annually by the International Society for Bioinformatics (ICSB) to one scientist for outstanding accomplishments in computational biology, and the Michael Bruno award. He was also elected as an EMBO member and as a member of the young Israeli academy of science. During the COVID-19 pandemic, Prof. Segal developed models for analyzing the dynamics of the pandemic and served as a senior advisor to the government of Israel.

Before joining the Weizmann Institute, Prof. Segal held an independent research position at Rockefeller University, New York.

Education: Prof. Segal was awarded a B.Sc. in Computer Science summa cum laude in 1998, from Tel-Aviv University, and a Ph.D. in Computer Science and Genetics in 2004, from Stanford University.

Lab website: http://genie.weizmann.ac.il

Dana Weiner. RD, MSc, director division of nutrition- sheba medical center
Nutritional Advisor to the Division of Government Hospitals
Leads the national program for the training of remote care for nutritionists
Leads training in nutrition at the end of life in the healthcare system
Nutrition lecturer for bachelor’s and master’s degrees
A partner in the development of technologies and applications in the field of nutrition
Leader in nutrition and health policy in the Ministry of Health
Consultant in the field of standardization and wages at the Ministry of Health

Sergey Jakimov is a founding partner of LongeVC, a venture capital company supporting early-stage biotech and longevity-focused founders that are changing the world. Sergey is a serial entrepreneur, having co-founded 3 deep-tech ventures (including Koatum and Vortex Oil Engineering) and raised more than $50 million in venture funding. He has advised several other startups in the therapeutics space on fundraising, IP protection, and clinical trial strategies. He is also a Visiting Lecturer to several universities on venture capital and intellectual property rights and co-authored a master’s program in Technology Law for the Riga Graduate School of Law.

Since 2018, he has led medical tech startup Longenesis, a cutting-edge company that unlocks the hidden value of biomedical data and accelerates novel drug treatment & discovery. Sergey holds a BSc in International Affairs from Rīga Stradiņš University and two MSc in Political Science and Government and Law and Finance from Central European University and Riga Graduate School of Law, respectively. He was named as a Forbes Latvia 30 Under 30 in technology and healthcare in 2020.

Dr. Wei-Wu He has been serving as Executive Chairman of Human
Longevity Inc. since July 2019. Dr. He is currently the Chairman of
CASI Pharmaceuticals, Inc., OriGene, Juventa, Sophonix and founder
of Genetron Health; Dr. He also is the founder and General Partner of
Emerging Technology Partners, LLC (ETP), a life sciences focused
venture fund established since 2000.
In the earlier part of his career, Dr. He was one of the first few
scientists at Human Genome Sciences, and prior to that, was a
research fellow at Massachusetts General Hospital and Mayo Clinic.
Dr. He is an author to more than 50 research publications and
inventor of over 32 issued patents.
Dr. Wei-Wu He received his PhD in Molecular Biology from Baylor
College of Medicine and received an MBA degree from the Wharton
School.

As a longevity enthusiast and lifelong tech geek, Dr. Rob Konrad believes that the more you know about
your body, the more you can improve your health and wellbeing – you can only manage what you can
measure! As CEO and Co-Founder of Biolytica, a Swiss health data enterprise, together with his team of
physicians, genetics experts, bioinformaticians, health coaches, dieticians, chronobiology experts, data
specialists and many others, he has created the first truly comprehensive health management platform,
Biolytica NEXUS, that integrates genetics, epigenetics, proteomics, labs and biomarkers, wearable device
data and much more to create truly personalized health optimization programs.

Prof. Tali Cukierman-Yaffe is an endocrinologist and a clinical epidemiologist. A senior
physician in the Endocrinology Institute, the head of the Centre for Successful Aging with
Diabetes at the Sheba Medical Centre, head of the Endocrinology & Diabetes service for
women &n pregnancy an associate professor at the Epidemiology department at Tel-Aviv
University and a member of the Herczeg institute on aging. She is also a PHRI (Population
Health Research Institute, Mcmaster University, Canada) senior international fellow.
The focus of her research is the relationship between diabetes and cognitive dysfunction and
the challenges of treating diabetes in older age. She has published many articles and has given
numerous talks on this topic, is part of working groups writing local and international guidelines
on this topic and is an invited advisor in forums dealing with this subject. Thus, she was PI of
the cognitive sub-study of the ORIGIN trial, a co-investigator of the ACCORD-MIND study and
took a key role in the cognitive sub-study of the REWIND trial that tested the cognitive safety
and efficacy of Dulaglutide in people with diabetes. In the last several years her research has
also been focused on finding technological solutions to improve the care of older people with
diabetes. Thus, she is the Principal investigator of a EFSD funded study aimed at developing a
technological solution for the replacement of traditional physical capacity assessments for older
people with diabetes and another study aimed at developing a digital Digit Substitution Test
(DSS) cognitive assessment tool.

Noam Maoz, PhD, is the co-founder and CTO of Centarix, a Jerusalem-based biotechnology company
focused on developing innovative longevity treatments to combat age-related decline. Driven by his
passion for advancing the field, Noam leads a multidisciplinary team at Centarix that is developing a
unique in-house panel of biological-age diagnostics, which is currently undergoing clinical trials.
Additionally, he is working on a novel cellular epigenetic rejuvenation approach and exploring
cutting-edge delivery methods.
Noam earned his PhD in molecular biology from Bar-Ilan University, where he studied genetic
manipulations targeting aging in eukaryotes. He then completed his postdoctoral training at Hebrew
University-Hadassah Medical School, focusing on cellular reprogramming, epigenetic mechanisms of
aging, and initiating a new approach for epigenetic rejuvenation.

PhD in Occupational Therapy.
Director of research and knowledge development at the division of health and function of older adults at JDC – Israel, Eshel.
Entrepreneur of fall prevention technology and among the developers and a faculty member of a recently opened leadership program for Master students: Function and Health for older adults at the School of Occupational Therapy, Faculty of Medicine, Hebrew University.

Wenbin Li, MD, PhD, chief Physician, professor,  director of cancer center and the Neuro-oncology department, Beijing Tiantan Hospital, Capital Medical University, vice president of the National Health Care Big Data (Capital Medical University) Research Institute, dean of the Department of Oncology in Capital Medical University, Chairman-designate of the Neuro-oncological Drug Clinical Research Committee, China Pharmaceutical Innovation and Research Development Association, deputy Chairman of the Gliomal Committee, Chinese Anti-Cancer Association, board member of “Signal Transduction and Targeted Therapy” and “Cancer Biology & Medical”, chief Editor of “Neuro-Tumor Channel of Medical Reference”. He is one of Leading Experts of Chinese and Western Medicine in Beijing, honorary Research Fellow of the University of South Florida. He is an expert in chemotherapy and clinical trials for brain tumors, was PI for two phase I clinical trials of China key innovative drugs during the 13th Five-Year Plan period. He is also the general coordinator in China for GBM AGILE international multi-center clinical trials.

Appointed Vice President for Research and Development in October 2017, Prof. Shulamit Michaeli previously served as Dean of the Mina and Everard Goodman Faculty of Life Sciences and the founding Director of the Nano-Medicine Center at the Bar-Ilan Institute for Nanotechnology and Advanced Materials (BINA). In addition, for eight years Professor Michaeli directed the Life Sciences and Medicine division of the Israel Science Foundation. Professor Michaeli has been a member of many national committees, including the prize committees for the Israel Prize and the EMET Prize. She has and participated and led European scientific associations, Israeli I-core excellence research centers, and other Israeli research groups.
A microbiologist by training and the Myers Chair in Gene Expression and Infectious Disease, Prof. Michaeli studies Trypanosomatids, the vicious order of parasites which infect millions worldwide, causing African sleeping sickness, South American Chagas disease, and leishmaniasis, or sand-fly fever, which affects a band of countries from Portugal through India, including Israel. Prof. Michaeli has pioneered the use of nanotechnology in fighting diseases creating nano-drugs for parasitic infections and cancer.
Prof. Michaeli has published more than a hundred and thirty papers in professional journals and books and patented a number of important technologies. She was the first researcher in the country to be funded by the Howard Hughes Medical Institute for ten years. She has won numerous prestigious awards, from the Israeli Society of Microbiology Award, both as a young researcher and as a senior research, and the Landau Prize, both in Medicine and more recently in Microbiology. She recently was awarded the Katzir prize. When she was on the staff of the Weizmann Institute, she was awarded the Clore Prize for Outstanding Young Researcher and the prestigious Andre Lwoff Prize in Parasitology given by the French Academy of Sciences. And twice she has been chosen as one of the 40 leading women in Israel by Globes newspaper. Most recently she was awarded an ERCsyng grant.
Professor Michaeli is married to Dr. Moshe Goldberg, ex-Director of Technological Infrastructure Research at the Ministry of Defense, and the mother of three children. Her daughter is an M.D.

Dr. Sara Bonnes is an associate professor of medicine at the Mayo Clinic, Rochester Minnesota. She is board certified in Internal Medicine, as well as a diplomat of the American College of lifestyle medicine, and physician nutrition specialist. With this unique intersection of clinical expertise, she has been asked to help develop their healthy longevity Clinic and research practice. She sees patients in the General Internal Medicine Consultative Medicine practice, intestinal failure Clinic, and healthy longevity Clinic.

In addition to her clinical interest and expertise, Dr. Bonnes remains a committed educator. She serves as vice chair of Education for the division of General Internal Medicine, and as an associate program director for their internal medicine residency.